Eduard G. Gemdzhian

Dr. Eduard G. Gemdzhian

Moscow, Russian Federation, National Medical Research Center for Hematology, Moscow, Moskva, Russia
orcid
PhD, Эдуард Гемджян, biostatistics, data science, bioinforma...

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2015 in Blood
Verified
Journal Article
Open access
GGGennadii M. Galstian
Gennadii M. Galstian
EPElena N. Parovichnikova
Elena N. Parovichnikova
PMPolina M. Makarova
Polina M. Makarova
LKLarisa A. Kuzmina
Larisa A. Kuzmina
VTVera V. Troitskaya
Vera V. Troitskaya
VSValeri G. Savchenko
Valeri G. Savchenko
Background: Recent evidence suggests that MSCs might improve survival during sepsis in animal models. However, no study has investigated the effects of MSC therapy on the survival of pts with sepsis and SS, especially severe-neutropenic pts. Aim: The aim of this study was to investigate the efficacy of the administration of MSCs for the treatment of SS in neutropenic pts. Patients and Methods: This prospective, single-center, randomized Russian clinical trial of MSCs in severe neutropenic pts with SS (RUMCESS) (NCT 01849237) was approved by the local ethics committee and was begun in December 2012. Neutropenic pts (WBC < 0.5x109/l) with SS were enrolled on to the study. The pts were randomly assigned (1:1) to receive either conventional therapy (CT) of SS (CT group), or CT plus donor MSCs at a dose of 106/kg intravenously within the first 10 hours after SS onset (CT+MSCs group). Written informed consent was obtained for all pts. All pts were admitted and treated in the ICU of the National Research Center for Hematology (Moscow). The Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sepsis-related Organ Failure Assessment (SOFA) score were employed to determine the severity of illness. Pts were followed up for 28 days after enrolment in the study, and 28-day all-cause mortality was assessed. Pts characteristics and complication rates were compared using Fisher's exact test. The Kaplan-Meier method with the log-rank test, and Cox proportional hazard regression model were used to determine the statistical significance of the relationship between overall survival (OS) and the treatment regimen. Statistical analyses were performed using SAS 9.1. Results: Of the 27 neutropenic pts with SS, 13 received CT and 14 received CT+MSCs. There were no statistically significant differences in the demographic variables between groups . The CT group included 7 males, 6 females, aged 33-81 yrs, median 55 yrs. The CT+MSCs group included 6 males, 8 females, aged 30-75 yrs, median 48 yrs. Hematological disorders were also similar in the two groups: AML (4), NHL (4), HL (1), MM (3), MDS (1) in the CT group, and AML (5), NHL (7), MM (1) in the CT+MSCs group. In all pts, except for one with MDS, neutropenia developed after chemotherapy. In 8/13 pts in the CT group and 9/14 pts in the CT+MSCs group blood cultures were found positive, mostly gram-negative. Baseline APACHE II scores (34.2 [95% CI 28.3-43.1] and 32.2 [95% CI 26.2-37.5] in the CT- and CT+MSC-groups, respectively), and SOFA scores (17.9 [95% CI 13.5-22.2] and 15.1 [95% CI 11.0-19.2] respectively), were similar in the two groups. 28-day survival rates were 15% (2 out of 13 pts) in the CT group and 57% (8 out of 14 pts) in the CT+MSCs group (P=0.04) (Figure 1). The significant increase in 28 days OS of the pts in CT+MCSs group was associated with SOFA score decrease, which was started in three days after onset of SS. Despite higher 28-day survival rates only 3 pts treated with CT+MSCs remained alive after 3 months, and 5 of 8 pts from the CT+MSCs-group who survived 28 days died later because of sepsis-related organ dysfunction. Conclusions: Administration of MSCs in the first hours of SS might improve short-term survival in neutropenic pts, but does not prevent death from sepsis-related organ dysfunction in the long term. Perhaps repeated administration of MSC is required.

1 January 2015 in Terapevticheskii arkhiv
Verified
Journal Article
Closed access
AMA. L. Melikyan
A. L. Melikyan
EEE. K. Egorova
E. K. Egorova
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
ISI. N. Subortseva
I. N. Subortseva
EGE. A. Gilyazitdinova
E. A. Gilyazitdinova
VSV. G. Savchenko
V. G. Savchenko
Издательство Медиа Сфера - 25 медицинских журналов общим тиражом около 500 000 экземпляров в год, представлены в международных базах данных Scopus, Medline, и Google Scolar, включены в перечень изданий ВАК, представлены в РИНЦ

1 July 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SSSvetlana Yu. Smirnova
Svetlana Yu. Smirnova
LALyubov S. Al-Radi
Lyubov S. Al-Radi
TMTatyana N. Moiseeva
Tatyana N. Moiseeva
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
IYIgor A. Yakutik
Igor A. Yakutik
ASAndrey Sudarikov
Andrey Sudarikov

1 January 2015 in Terapevticheskii arkhiv
Verified
Journal Article
Closed access
EBE. A. Baryakh
E. A. Baryakh
NTN. G. Tyurina
N. G. Tyurina
VVV. I. Vorobyev
V. I. Vorobyev
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
YMYa. K. Mangasarova
Ya. K. Mangasarova
SKS. K. Kravchenko
S. K. Kravchenko
To evaluate the efficiency and toxicity of the intensive Burkitt's lymphoma (BL) therapy protocol BL-M-04. A total of 70 patients diagnosed with BL, including 45 men and 25 women whose age was 15 to 62 years (median age 31 years), were followed up in 2003 to 2014. Stage I (according to S. Murphy) was diagnosed in 4 (5.7%) patients; II in 9 (12.9%), III in 25 (35.7%), IV in 11 (15.7%), and Burkitt's leukemia in 21 (30%). There were tumor involvements of the bone marrow and central nervous system in 23 (32.9%) and 15 (21.4%) patients, respectively. B symptoms were detected in 56 (80%) patients; enhanced lactate dehydrogenase (LDH) activity was found in 50 (78.1%) out of 64 patients; moreover, in 34 (56.2%) out of 64 patients, LDH activity was more than twice as high as the reference values. The median LDH activity was 2398 (238-20,300) U/I. Acute renal failure at disease onset was identified in 17 (24.2%) patients; chemotherapy was initiated in 8 patients during renal replacement therapy. The treatment was performed using the BL-M-04±R protocol (4 successive blocks of A-C-A-C±R). Six blocks of A-C-A-C-A-C with rituximab has been carried out in patients with bone marrow involvement since 2011. Sixty-two (89%) patients achieved complete remission. At this time, 6 patients died from therapy complications during remission induction; 2 patients were observed to have disease progression; 3 developed disease recurrence (2 patients had early recurrence; 1 patient developed recurrence 2 years after treatment). Five-year overall survival (OS) was 85%; 5-year relapse-free survival (RFS) was 95%. The Cox multivariate regression analysis revealed that Burkitt's leukemia and bone marrow involvement were independent factors that influenced OS and RFS. The poor somatic status (3-4 ECOC scores versus 0-2 scores) proved to be statistically significant for OS rather than RFS. Despite the optimistic results obtained by our study group, there is a need to further improve BL treatment protocols and to elaborate novel approaches to therapy particularly for older patients and patients with Burkitt's leukemia.

1 January 2016 in Terapevticheskii arkhiv
Verified
Journal Article
Closed access
SSS. V. Shtyrkova
S. V. Shtyrkova
GKG. A. Klyasova
G. A. Klyasova
KNK. I. Ntanishyan
K. I. Ntanishyan
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
VTV. V. Troitskaya
V. V. Troitskaya
СКС. Р. Карагюлян
С. Р. Карагюлян
Induction CT cycles, the status of granulocytopenia, and the presence of infection sources in the anal canal as an anal fissure, skin ulcerations, or a fistula should be considered as independent statistically significant prognostic risk factors for PI. The number of granulocytes determines the form of inflammation, the course of infection, and the chance of developing sepsis. The effective prevention encompassing surgical treatment for anal canal diseases reduces the risk of septic complications and the number of paraproctitis recurrences, contributing to the implementation of a planned CT program in patients with hemoblastosis.

19 August 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NZN.G. Zvonkova
N.G. Zvonkova
TBT.E. Borovik
T.E. Borovik
VCV.V. Chernikov
V.V. Chernikov
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
SYS.P. Yatsyk
S.P. Yatsyk
MEMoscow Russian Medical Academy For Continuous Professional Education
Moscow Russian Medical Academy For Continuous Professional Education
Malnutrition (MN) is common in children with acute and chronic illnesses. The use of questionnaires to assess nutritional risk in children admitted to hospital is a simple and quick way to identify patients who need nutritional advice and nutritional support. Various English-language screening questionnaires, such as STRONGkids nutritional risk screening tool for children, in particular, have been developed and validated. The purpose of the study is to adapt the STRONGkids nutritional risk screening tool for the Russian language speaking audience and to determine the reliability and validity of its new language version. Materials and methods of research: linguistic ratification of the STRONGkids questionnaire was carried out and the Russian language version was created. This single-center prospective study included 419 children admitted from October, 2019 to March, 2021 for treatment in Therapeutic Pediatric (cardiac, nephrological, gastroenterological, pulmonological etc.) and Surgical Pediatric (abdominal, thoracic, otorhinolaryngological, cardiosurgical etc.) Departments of the National Medical Research Center for Children’s Health (Moscow, Russia) with a hospital stay longer than a single day. The reliability of the questionnaire was assessed in 50 children. The anthropometric indicators were used to assess the current validity; the duration of hospitalization was used to assess the predictive validity. Body mass index-for-age (BMI-for-age) <-2SD and Length/height-for-age <-2SD z-scores were criteria for acute and chronic MN, respectively. Results: almost complete (κ=0.84) inter-expert agreement was found during the evaluation of reliability of the STRONGkids questionnaire. The validation study included 419 patients (51% boys/49% girls) aged from 1 month till 17 years and 11 months old (8 years old as median) with hospitalization duration from 1 to 100 days (10 days as median), of which 314 (75%) and 105 (25%) therapeutic pediatric and surgical pediatric patients, respectively. The frequency of acute and chronic MN at admission was 9.1% and 7.4%, respectively, and the percentage of children at low, moderate and high risk (assessed by the questionnaire) was 22.7%, 66.6% and 10.7%, respectively. Children at nutritional risk had statistically significantly (p<0.05) lower BMI-for-age and Length/height-for-age z-scores, greater incidence of MN and longer hospital stays than patients without nutritional risk. A chronic disease addendum, complications and high nutritional risk according to the questionnaire are independent unfavorable factors for an increase in the duration of hospitalization. Conclusion: the Russian language version of the STRONGkids nutritional risk screening tool for children was adapted and validated to assess nutritional risk in children admitted to hospital for treatment. Since right now it can be of use for identifying patients at high risk of MN for the purpose of their additional examination and timely administration of nutritional support and can be used both in routine pediatric clinical practice and in purpose of further scientific research.